Peptide record

TPDB25637

Antibacterial Antiviral Toxicity standard
21 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB25637
Antibacterial Antiviral Toxicity
Anti-infective peptides Toxicity and safety peptides
Peptipedia AI4AVP dbAMP 3.0 DRAVP 2.0
standard
No
A 21-aa standard natural multi-activity (Antibacterial, Antiviral, and Toxicity) peptide sequence curated from Peptipedia, AI4AVP, dbAMP 3.0, and other sources, with an available 3D structural model.
Sequence
SKEKIGKEFKRIVQRIKDFLR
Physicochemical Analysis
C119H204N36O30
ANCHMPTWY
K
2619.15
11.06
8
3
7
+5
9.69
-1.005
88.10
Mammalian: 1.9 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
2
Residue Composition
number
0
A
3
R
0
N
1
D
0
C
2
E
1
Q
1
G
0
H
3
I
1
L
5
K
0
M
2
F
0
P
1
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 0 R: 3 N: 0 D: 1 C: 0 E: 2 Q: 1 G: 1 H: 0 I: 3 L: 1 K: 5 M: 0 F: 2 P: 0 S: 1 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
21
C119H204N36O30
2619.15
11.06
+5
9.69
-1.005
Evidence Records 4 records
Evidence 1 Activity

Activity

Antibacterial

Source & Reference

NA

Other

inhibited Human Immunodeficiency Virus Type 1 HIV-1 (EC50 10.8 uM).
Evidence 2 Activity

Activity

Antiviral

Source & Reference

dbAMP 3.0 DRAVP 2.0

Other

Source Activity Label Source Definition
Antiviral
dbAMP 3.0 classified under the Anti-viral function class.
inhibited Human Immunodeficiency Virus Type 1 HIV-1 (EC50 10.8 uM).
Evidence 3 Activity

Activity

50% cell death
Toxicity
22.5 µM
Cytotoxic
50% cell death | 22.5 | µM | target cell: CEM-SS cells

Target

CEM-SS cells

Source & Reference

NA
DBAASP
Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins | Antimicrob Agents Chemother | 2008
Evidence 4 Activity

Activity

Toxicity
Cytotoxic
Cytotoxicity: [Ref.18591279]CEM-SS cells:TC50=22.5 µM.(TC50:the concentration that reduced cell viability by 50%)

Source & Reference

NA
DRAMP
Antimicrob Agents Chemother. 2008 Sep 52(9):3438-40.